Holen Sie sich die Stockscreener-App
7.935
2.09%
-0.185
Schlusskurs vom Vortag:
$8.12
Offen:
$8.06
24-Stunden-Volumen:
82,505
Relative Volume:
0.32
Marktkapitalisierung:
$253.99M
Einnahmen:
$128.45M
Nettoeinkommen (Verlust:
$6.54M
KGV:
158.70
EPS:
0.05
Netto-Cashflow:
$-8.79M
1W Leistung:
-3.99%
1M Leistung:
+17.43%
6M Leistung:
+7.00%
1J Leistung:
+68.43%
1-Tages-Spanne:
$7.87
$8.06
1-Wochen-Bereich:
$7.87
$8.6299
52-Wochen-Spanne:
$3.6793
$8.6299
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Firmenname
Lifecore Biomedical Inc
Sektor
Telefon
(952) 368-4300
Adresse
3515 LYMAN BOULEVARD, CHASKA
Vergleichen Sie LFCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
7.95 | 253.99M | 128.45M | 6.54M | -8.79M | 0.05 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.02 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.36 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Eingeleitet | William Blair | Outperform |
| 2024-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-28 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | Herabstufung | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten
Lifecore Biomedical: Inflecting Financials Over Next 3 Years (NASDAQ:LFCR) - Seeking Alpha
Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy - Nasdaq
Lifecore Biomedical Q3 2025 slides: Revenue dip amid ambitious growth strategy By Investing.com - Investing.com South Africa
Lifecore signs 10-year manufacturing deal with key ophthalmic client By Investing.com - Investing.com Nigeria
Lifecore Biomedical Q3 2025 slides: Revenue dip amid ambitious growth strategy - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - ACCESS Newswire
Lifecore Biomedical Enters 10-Year Commercial Manufacturing & Supply Agreement with Existing Customer - Contract Pharma
2025-06-17 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect | NDAQ:LFCR | Press Release - Stockhouse
Lifecore signs 10-year manufacturing deal with key ophthalmic client - Investing.com
Lifecore (LFCR) Secures Decade-Long Manufacturing Deal for Ophth - GuruFocus
Lifecore Biomedical Signs 10-Year Manufacturing, Supply Deal With Ophthalmic Therapy Customer - MarketScreener
Lifecore (LFCR) Secures Decade-Long Manufacturing Deal for Ophthalmic Therapy | LFCR Stock News - GuruFocus
Lifecore Biomedical Signs 10-Year Commercial Manufacturing Agreement to Advance Novel Ophthalmic Therapeutic - Nasdaq
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer - GlobeNewswire
Lifecore Biomedical Lands Multi-Million Dollar, 10-Year Manufacturing Contract for Novel Eye Treatment - Stock Titan
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Purchased by Bank of America Corp DE - Defense World
Lifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment sale - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Lifecore receives early $10 million payment for equipment sale By Investing.com - Investing.com South Africa
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale - GlobeNewswire
Lifecore Receives Full Payment Early For $17 Mln Equipment Sale - Nasdaq
Lifecore Biomedical Receives Remaining $10 Million for Sale of Isolator Filler Ahead of Schedule - marketscreener.com
Lifecore (LFCR) Completes $10 Million Equipment Sale Payment | LFCR Stock News - GuruFocus
Lifecore receives early $10 million payment for equipment sale - Investing.com Australia
Lifecore Biomedical Fast-Tracks $10M Equipment Payment as New Filler Promises $300M Revenue Potential - Stock Titan
2025-06-10 | Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation | NDAQ:LFCR | Press Release - Stockhouse
Squarepoint Ops LLC Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
(LFCR) Long Term Investment Analysis - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Deutsche Bank AG Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Contrasting Lifecore Biomedical (NASDAQ:LFCR) & Liquidia (NASDAQ:LQDA) - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by BNP Paribas Financial Markets - Defense World
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifecore Biomedical (NASDAQ:LFCR) shareholders have endured a 37% loss from investing in the stock five years ago - Yahoo Finance
How the (LFCR) price action is used to our Advantage - news.stocktradersdaily.com
Lifecore appoints new chief commercial officer to drive growth By Investing.com - Investing.com South Africa
Lifecore Biomedical Appoints CCO - Contract Pharma
Lifecore Biomedical Names Mark Dafonseca Chief Commercial Officer - marketscreener.com
LFCR Appoints New Chief Commercial Officer | LFCR Stock News - GuruFocus
Lifecore appoints new chief commercial officer to drive growth - Investing.com
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer - GlobeNewswire
Lifecore Biomedical Taps 30-Year Pharma Veteran as CCO to Accelerate CDMO Market Expansion - Stock Titan
Northern Trust Corp Purchases 28,019 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Analysts Set Expectations for LFCR Q4 Earnings - Defense World
William Blair Begins Coverage on Lifecore Biomedical (NASDAQ:LFCR) - Defense World
What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies? - Insider Monkey
Lifecore Biomedical (LFCR) Receives 'Outperform' Rating from Wil - GuruFocus
Lifecore stock gains on Outperform rating by William Blair - Investing.com Canada
Finanzdaten der Lifecore Biomedical Inc-Aktie (LFCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lifecore Biomedical Inc-Aktie (LFCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| English Aron R. | 10% Owner |
May 28 '25 |
Sale |
7.12 |
150,419 |
1,071,555 |
264,180 |
| English Aron R. | 10% Owner |
May 23 '25 |
Sale |
6.75 |
96,137 |
649,386 |
1,554,103 |
| English Aron R. | 10% Owner |
May 13 '25 |
Sale |
7.00 |
12,334 |
86,353 |
1,650,240 |
| English Aron R. | 10% Owner |
May 12 '25 |
Sale |
7.03 |
45,698 |
321,426 |
1,662,574 |
| English Aron R. | 10% Owner |
May 08 '25 |
Sale |
7.00 |
5,098 |
35,693 |
1,708,972 |
| English Aron R. | 10% Owner |
May 09 '25 |
Sale |
7.00 |
700 |
4,900 |
1,708,272 |
| English Aron R. | 10% Owner |
May 05 '25 |
Sale |
7.08 |
24,543 |
173,831 |
1,730,618 |
| English Aron R. | 10% Owner |
May 07 '25 |
Sale |
7.01 |
15,847 |
111,099 |
1,714,070 |
| English Aron R. | 10% Owner |
May 06 '25 |
Sale |
7.05 |
701 |
4,940 |
1,729,917 |
| Josephs Paul | Chief Executive Officer |
Jan 08 '25 |
Buy |
5.74 |
17,000 |
97,580 |
559,717 |
0.84%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):